Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A fixed-dose combination regimen of **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A) and **toripalimab** (a humanized monoclonal antibody targeting programmed cell death protein 1), used in the treatment of advanced and unresectable hepatocellular carcinoma, metastatic cervical cancer, and other solid tumors. Bevacizumab acts as an anti-angiogenic agent, inhibiting tumor blood vessel formation, while toripalimab blocks the PD-1 immune checkpoint on T-cells, enhancing anti-tumor immunity. This combination is developed to leverage dual mechanisms: improving immune response and altering the tumor microenvironment via VEGF inhibition, creating synergy in cancer therapy[1][3][4][5][8].
- Brand names
- Avastin (bevacizumab)Loqtorzi (toripalimab)
- Other names
- toripalimab plus bevacizumabbevacizumab and toripalimab combination
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + toripalimab.